Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Receivables: 2012-2024

Historic Change in Receivables for Akebia Therapeutics (AKBA) over the last 12 years, with Dec 2024 value amounting to -$4.0 million.

  • Akebia Therapeutics' Change in Receivables fell 356.13% to -$6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year increase of 279.14%. This contributed to the annual value of -$4.0 million for FY2024, which is 307.04% down from last year.
  • According to the latest figures from FY2024, Akebia Therapeutics' Change in Receivables is -$4.0 million, which was down 307.04% from -$994,000 recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' Change in Receivables registered a high of $24.0 million during FY2021, and its lowest value of -$11.7 million during FY2020.
  • Moreover, its 3-year median value for Change in Receivables was -$4.0 million (2024), whereas its average is -$5.4 million.
  • Per our database at Business Quant, Akebia Therapeutics' Change in Receivables soared by 305.90% in 2021 and then plummeted by 307.04% in 2024.
  • Akebia Therapeutics' Change in Receivables (Yearly) stood at -$11.7 million in 2020, then soared by 305.90% to $24.0 million in 2021, then slumped by 147.02% to -$11.3 million in 2022, then spiked by 91.20% to -$994,000 in 2023, then plummeted by 307.04% to -$4.0 million in 2024.